Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07700745
Active, not recruiting Not applicable

A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin

NCT07700745 · tracked via the Priya Life Science USA tracker
Sponsor
Rejuvaskin
Phase
Not applicable
Started
2026-07-06
Last updated
2026-07-14

Condition(s) studied

EczemaAtopic DermatitisEczema-Prone Skin

Investigational drug(s) / intervention(s)

Rejuvaskin Eczema Body Wash

Rejuvaskin Eczema Body Wash: Participants use Rejuvaskin Eczema Body Wash once daily during a shower or bath in place of their usual body cleanser, followed by application of Rejuvaskin Skin Recovery Cream, for 4 consecutive weeks.

Study summary

This is a single-arm, open-label, decentralized (fully remote) clinical trial evaluating the tolerability and self-perceived skin effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in 35 adults aged 18-65 with self-reported eczema-prone skin. Participants will use the body wash once daily in place of their usual cleanser, followed by the Skin Recovery Cream, for 4 consecutive weeks.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Adult women or men aged 18-65 years. * Self-reported symptoms of eczema or eczema-prone skin (e.g., dryness, roughness, itching, irritation on the body). * Visible signs of eczema such as dryness, roughness, or irritation on at least one part of the body at the time of enrollment. * Willing to use Rejuvaskin Eczema Body Wash once daily as their primary body cleanser for 4 consecutive weeks. * Willing to use Rejuvaskin Skin Recovery Cream once daily after using the - Rejuvaskin body cleanser for 4 consecutive weeks. * Willing to maintain their current diet, skincare routine (aside from substitution of body wash and skin cream), and lifestyle habits for the study duration. * Willing and able to take standardized photographs of an affected body area at Baseline and Week 4 using a personal smartphone. * Able to read, understand, and complete questionnaires in English. * Resides in the United States with a valid shipping address. * Willing to provide informed consent and comply with all study procedures Exclusion Criteria: * Known allergy or sensitivity to any ingredient in the study product. * Currently pregnant, breastfeeding, or planning to become pregnant during the study period. * Active, severe skin condition on the body requiring prescription topical or systemic treatment (e.g., active severe atopic dermatitis flare under medical care, active infection at intended application sites). * Currently using prescription topical corticosteroids, calcineurin inhibitors, or other prescription topical eczema treatments on the body, or initiation of such treatment planned during the study. * Currently participating in another clinical or skincare research study, or planning to enroll during this study's duration. (

Primary outcome measure(s)

  • Change from Baseline in Self-Reported Skin Dryness — Baseline to Week 4
    Mean change in self-reported dryness measured via a structured self-report questionnaire administered through the Citruslabs platform
  • Change from Baseline in Self-Reported Skin Roughness — Baseline to Week 4
    Mean change in self-reported roughness measured via a structured self-report questionnaire administered through the Citruslabs platform
  • Change from Baseline in Self-Reported Skin Itch — Baseline to Week 4
    Mean change in self-reported itch measured via a structured self-report questionnaire administered through the Citruslabs platform
  • Change from Baseline in Self-Reported Skin Irritation — Baseline to Week 4
    Mean change in self-reported irritation measured via a structured self-report questionnaire administered through the Citruslabs platform
  • Change from Baseline in Self-Reported Skin Discomfort — Baseline to Week 4
    Mean change in self-reported discomfort measured via a structured self-report questionnaire administered through the Citruslabs platform

Trial sites (1)

FacilityCityRegionStatus
Citruslabs Las Vegas Nevada

Other trials for the same condition

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis Active, not recruiting
Investigating Participation Patterns of Patients in Atopic Dermatitis Clinical Trials Starting soon
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema Recruiting
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis Active, not recruiting
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07700745 on ClinicalTrials.gov ↗ ← All trials in the USA